Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 11 (November)

1. Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer.
   Int J Cancer, 119(12): 2733-41. [Abstract] [Full-text]
2. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.
   Int J Cancer, 119(12): 2907-15. [Abstract] [Full-text]
3. Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells.
   Prostate, 66(16): 1788-98. [Abstract] [Full-text]
4. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
   N Engl J Med, 355(18): 1851-62. [Abstract] [Full-text]
5. Medication errors related to computerized order entry for children.
   Pediatrics, 118(5): 1872-9. [Abstract] [Full-text]
6. Transfection activity of binary mixtures of cationic o-substituted phosphatidylcholine derivatives: the hydrophobic core strongly modulates physical properties and DNA delivery efficacy.
   Biophys J, 91(10): 3692-706. [Abstract] [Full-text]
7. Perioperative fluid management in renal transplantation: a narrative review of the literature.
   Transpl Int, 19(12): 947-59. [Abstract] [Full-text]
8. Shell-crosslinked Pluronic L121 micelles as a drug delivery vehicle.
   Biomaterials, 28(4): 725-34. [Abstract] [Full-text]
9. Biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics.
   Biomaterials, 28(4): 717-24. [Abstract] [Full-text]
10. The alveolar-epithelial barrier: a target for potential therapy.
    Clin Chest Med, 27(4): 655-69; abstract ix. [Abstract] [Full-text]
11. Pulmonary artery catheter and fluid management in acute lung injury and the acute respiratory distress syndrome.
    Clin Chest Med, 27(4): 627-35; abstract ix. [Abstract] [Full-text]
12. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Int J Cancer, 120(1): 181-8. [Abstract] [Full-text]
13. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Int J Cancer, 120(1): 160-9. [Abstract] [Full-text]
14. Adherence behaviour with psychotropic medication is a form of self-medication.
    Med Hypotheses, 68(1): 12-21. [Abstract] [Full-text]
15. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy.
    Med Hypotheses, 68(1): 188-93. [Abstract] [Full-text]
16. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma.
    Biomaterials, 28(5): 886-94. [Abstract] [Full-text]
17. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
    Biomaterials, 28(5): 869-76. [Abstract] [Full-text]
18. The role of medication use and health on the decision to quit drinking among older adults.
    J Aging Health, 18(6): 837-51. [Abstract] [Full-text]
19. B-type natriuretic peptide to assess haemodynamic status after cardiac surgery.
    Br J Anaesth, 97(6): 777-82. [Abstract] [Full-text]
20. Gadolinium diethylenetriaminopentaacetic acid-loaded chitosan microspheres for gadolinium neutron-capture therapy.
    Carbohydr Res, 341(17): 2835-41. [Abstract] [Full-text]
21. Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the Nutrition for Healthy Living cohort.
    J Acquir Immune Defic Syndr, 43(4): 475-82. [Abstract] [Full-text]
22. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.
    J Acquir Immune Defic Syndr, 43(4): 451-7. [Abstract] [Full-text]
23. Non-invasive prediction of fluid responsiveness during major hepatic surgery.
    Br J Anaesth, 97(6): 808-16. [Abstract] [Full-text]
24. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury.
    J Acquir Immune Defic Syndr, 43(4): 383-92. [Abstract] [Full-text]
25. Effects of highly active antiretroviral therapy and immune recovery on CD8+ T-cell-mediated inhibition of HIV-1 transcription.
    J Acquir Immune Defic Syndr, 43(4): 393-400. [Abstract] [Full-text]
26. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder.
    Neurology, 67(9): 1692-4. [Abstract] [Full-text]
27. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.
    Circulation, 114(20): 2148-53. [Abstract] [Full-text]
28. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.
    Circulation, 114(20): 2154-62. [Abstract] [Full-text]
29. Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response.
    Biochem Biophys Res Commun, 351(3): 702-7. [Abstract] [Full-text]
30. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Am J Hematol, 81(12): 973-8. [Abstract] [Full-text]
31. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Cancer Res, 66(22): 10959-66. [Abstract] [Full-text]
32. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
    Cancer Res, 66(22): 10953-8. [Abstract] [Full-text]
33. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
    J Natl Cancer Inst, 98(22): 1647-54. [Abstract] [Full-text]
34. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    JAMA, 296(19): 2351-61. [Abstract] [Full-text]
35. Brief report: beta-blocker use among veterans with systolic heart failure.
    J Gen Intern Med, 21(12): 1306-9. [Abstract] [Full-text]
36. Effect of dysthymia on receipt of HAART by minority HIV-infected women.
    J Gen Intern Med, 21(12): 1235-41. [Abstract] [Full-text]
37. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy.
    J Gen Intern Med, 21(12): 1215-21. [Abstract] [Full-text]
38. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.
    J Am Acad Dermatol, 55(6): 1092-4. [Abstract] [Full-text]
39. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy.
    J Invest Dermatol, 126(12): 2679-86. [Abstract] [Full-text]
40. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens.
    Bone Marrow Transplant, 38(11): 739-43. [Abstract] [Full-text]
41. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
    J Clin Oncol, 24(33): 5271-6. [Abstract] [Full-text]
42. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    J Clin Oncol, 24(33): 5247-52. [Abstract] [Full-text]
43. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    J Clin Oncol, 24(33): 5242-6. [Abstract] [Full-text]
44. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    J Clin Oncol, 24(33): 5201-6. [Abstract] [Full-text]
45. Progression of middle cerebral artery susceptibility sign on T2*-weighted images: its effect on recanalization and clinical outcome after thrombolysis.
    AJR Am J Roentgenol, 187(6): W650-7. [Abstract] [Full-text]
46. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    J Clin Oncol, 24(33): 5194-200. [Abstract] [Full-text]
47. Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.
    Br J Ophthalmol, 90(12): 1524-30. [Abstract] [Full-text]
48. Evaluation response and effectiveness of thyroid hormone replacement treatment on lipid profile and function in elderly patients with subclinical hypothyroidism.
    Arch Gerontol Geriatr, 44(1): 13-9. [Abstract] [Full-text]
49. Synergistic effects of recombinant human soluble thrombomodulin and fluid-volume resuscitation in a rat lethal crush injury model.
    Shock, 26(6): 581-6. [Abstract] [Full-text]
50. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Cancer Chemother Pharmacol, 59(1): 17-21. [Abstract] [Full-text]
51. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
    Cancer Chemother Pharmacol, 59(1): 113-26. [Abstract] [Full-text]
52. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Cancer Chemother Pharmacol, 59(1): 51-9. [Abstract] [Full-text]
53. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 59(1): 1-7. [Abstract] [Full-text]
54. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
    Cancer Chemother Pharmacol, 59(1): 9-15. [Abstract] [Full-text]
55. Amine-containing core-shell nanoparticles as potential drug carriers for intracellular delivery.
    J Biomed Mater Res A, 80(1): 184-93. [Abstract] [Full-text]
56. Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices.
    J Biomed Mater Res A, 80(1): 13-23. [Abstract] [Full-text]
57. A system and process redesign to improve perioperative antibiotic administration.
    Anesth Analg, 103(6): 1517-21. [Abstract] [Full-text]
58. Arterial versus plethysmographic dynamic indices to test responsiveness for testing fluid administration in hypotensive patients: a clinical trial.
    Anesth Analg, 103(6): 1478-84. [Abstract] [Full-text]
59. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis.
    Ann Thorac Surg, 82(6): 1976-81. [Abstract] [Full-text]
60. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
    Cancer, 107(11): 2589-96. [Abstract] [Full-text]
61. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Cancer, 107(11): 2688-97. [Abstract] [Full-text]
62. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
    Fertil Steril, 86(6): 1669-75. [Abstract] [Full-text]
63. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
    Cancer, 107(11): 2678-87. [Abstract] [Full-text]
64. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy.
    Cancer, 107(11): 2662-8. [Abstract] [Full-text]
65. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Cancer, 107(11): 2535-44. [Abstract] [Full-text]
66. Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome.
    Fertil Steril, 86(6): 1710-5. [Abstract] [Full-text]
67. Medication errors in children.
    Pediatr Clin North Am, 53(6): 1155-68. [Abstract] [Full-text]
68. The incidence of adverse events and medical error in pediatrics.
    Pediatr Clin North Am, 53(6): 1067-77. [Abstract] [Full-text]
69. The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-(10)B (GB-10) as (10)B-carriers for boron neutron capture therapy.
    Int J Radiat Oncol Biol Phys, 66(5): 1515-22. [Abstract] [Full-text]
70. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery.
    Br J Surg, 93(12): 1469-74. [Abstract] [Full-text]
71. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Int J Radiat Oncol Biol Phys, 66(5): 1384-90. [Abstract] [Full-text]
72. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
    Int J Radiat Oncol Biol Phys, 66(5): 1391-8. [Abstract] [Full-text]
73. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
    Eur J Public Health, 16(6): 601-8. [Abstract] [Full-text]
74. New developments in fluid resuscitation.
    Surg Clin North Am, 87(1): 55-72, vi. [Abstract] [Full-text]
75. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients.
    Int J Cardiol, 114(1): 104-5. [Abstract] [Full-text]
76. Severe botulism after focal injection of botulinum toxin.
    Neurology, 67(10): 1855-6. [Abstract] [Full-text]
77. Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?
    Stroke, 37(12): 2963-9. [Abstract] [Full-text]
78. Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
    Stroke, 37(12): 2880-5. [Abstract] [Full-text]
79. Long-term effect of intra-arterial thrombolysis in stroke.
    Stroke, 37(12): 3002-7. [Abstract] [Full-text]
80. The effects of saline or albumin resuscitation on acid-base status and serum electrolytes.
    Crit Care Med, 34(12): 2891-7. [Abstract] [Full-text]
81. Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes.
    Diabetes, 55(12): 3529-35. [Abstract] [Full-text]
82. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    J Clin Oncol, 24(34): 5408-13. [Abstract] [Full-text]
83. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors.
    J Clin Oncol, 24(34): 5403-7. [Abstract] [Full-text]
84. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
    J Clin Oncol, 24(34): 5381-7. [Abstract] [Full-text]
85. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
    J Clin Oncol, 24(34): 5366-72. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.